Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
1g |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
Other Sizes |
|
Purity: ≥98%
Dopamine HCl (formerly Intropin; Dopamine HCl; ASL 279; ASL279; P 498; 3-Hydroxytyramine, ASL-279 and Intropin), the hydrochloride salt of dopamine, is an endogenous catecholamine neurotransmitter found in a wide variety of animals, it is a dopamine D1-5 receptors agonist. Dopamine HCl is a major catecholamine neurotransmitter derived from the amino acid tyrosine and serves as the precursor to norepinephrine and epinephrine. Dopamine is known to elevate heart rate and to activate multiple dopamine receptors.
Targets |
Microbial Metabolite; D2 Dopamine Receptor
|
---|---|
ln Vitro |
Vascular permeability cells/vascular endothelial growth cells (VPF/VEGF) strongly stimulate the proliferation of human venous endothelial cells (HUVEC). The stimulatory effect of VPF/VEGF is abolished by dopamine hydrochloride (1 μM; 24 h) [2]. Cell proliferation assay[2] Cell line: HUVEC Concentration: 1 µM Incubation time: 24 hours Results: Specific inhibition of VPF/VEGF-induced HUVEC proliferation through its D2 receptor.
|
ln Vivo |
Dopamine hydrochloride (50 mg/kg; intraperitoneal injection; days 1-7) strongly and locally inhibits the vascular permeabilization and angiogenic activities of VPF/VEGF [2]. Animal model: MOT ascites tumor syngeneic C3Heb/FeJ mice [2] Dosage: 50 mg/kg Administration method: intraperitoneal injection; 7-day results: equivalent to approximately 5% of the mouse median lethal dose (LD50), from the tumor Started 24 hours after cell injection and continued daily for 7 days.
|
Cell Assay |
Cell Line: HUVECs
Concentration: 1 µM Incubation Time: 24 hours Result: Inhibited VPF/VEGF-induced HUVEC proliferation specifically through its D2 receptor. |
Animal Protocol |
Syngeneic C3Heb/FeJ mice with MOT ascites tumors
50 mg/kg I.p. injection; 7 days |
References |
Molecular Formula |
C8H12CLNO2
|
|
---|---|---|
Molecular Weight |
189.64
|
|
Exact Mass |
189.06
|
|
Elemental Analysis |
C, 50.67; H, 6.38; Cl, 18.69; N, 7.39; O, 16.87
|
|
CAS # |
62-31-7
|
|
Related CAS # |
Dopamine; 51-61-6
|
|
Appearance |
Solid powder
|
|
SMILES |
C1=CC(=C(C=C1CCN)O)O.Cl
|
|
InChi Key |
CTENFNNZBMHDDG-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C8H11NO2.ClH/c9-4-3-6-1-2-7(10)8(11)5-6;/h1-2,5,10-11H,3-4,9H2;1H
|
|
Chemical Name |
4-(2-aminoethyl)benzene-1,2-diol;hydrochloride
|
|
Synonyms |
|
|
HS Tariff Code |
2934.99.9001
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 5.2731 mL | 26.3657 mL | 52.7315 mL | |
5 mM | 1.0546 mL | 5.2731 mL | 10.5463 mL | |
10 mM | 0.5273 mL | 2.6366 mL | 5.2731 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT02965963 | Active Recruiting |
Drug: Dopamine Other: Rest Drug: Placebos Drug: Metoclopramide |
Health | University of Alberta | December 2016 | Not Applicable |
NCT04128683 | Active Recruiting |
Drug: amisulpride Drug: bromocriptine |
Anorexia Nervosa | University of California, San Diego |
October 20, 2020 | Early Phase 1 |
NCT05369533 | Active Recruiting |
Device: Telerehabilitation Drug: Sinemet Pill Drug: Placebo |
Stroke | University of California, Los Angeles |
August 1, 2022 | Phase 1 Phase 2 |
NCT02815917 | Active Recruiting |
Drug: [18F]FTP PET/CT | Healthy Volunteer Cocaine-dependent D3 Dopamine Receptor |
University of Pennsylvania | June 2016 | Phase 1 Phase 2 |
NCT04937452 | Active Recruiting |
Drug: Rotigotine 4Mg/24Hrs Patch Drug: Placebo |
Dementia Aphasia Brain Diseases |
I.R.C.C.S. Fondazione Santa Lucia |
June 3, 2021 | Phase 2 |